Gilead (GILD) Lags Other Biotechs Following HCV Data From Regulus (RGLS)

Gilead Sciences (NASDAQ: GILD) shares declined Wednesday, falling over 1.5% despite gains in the Nasdaq biotech index, which was up 2.75%.

Softness in shares of Gilead follows positive data from Regulus Therapeutics (NASDAQ: RGLS). Earlier Regulus announced encouraging interim results from its ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection.

In a research note, Jefferies analyst Brian Abrahams said RG-101 may be disruptive in HCV but the threat to Gilead was "unclear."

You May Also Be Interested In

• Jefferies Downgrades Nutrien (NTR) to Hold
• U.S. Bancorp (USB) PT Raised to $74 at DA Davidson
• Bright Horizons (BFAM) PT Lowered to $87 at UBS Ahead of Q2 Results